AKBA Covered Call Strategy
AKBA (Akebia Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AKBA (Akebia Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $234.1M, a beta of 0.24 versus the broader market, a 52-week range of 0.823-3.32, average daily share volume of 4.6M, a public-listing history dating back to 2014, approximately 194 full-time employees. These structural characteristics shape how AKBA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.24 indicates AKBA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a covered call on AKBA?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
AKBA snapshot
As of August 14, 2026, spot at $0.88, ATM IV 31.30%, IV rank 2.70%, expected move 8.97%. The covered call on AKBA below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this covered call structure on AKBA specifically: AKBA IV at 31.30% is on the cheap side of its 1-year range, which means a premium-selling AKBA covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 8.97% (roughly $0.08 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AKBA expiries trade a higher absolute premium for lower per-day decay. Position sizing on AKBA should anchor to the underlying notional of $0.88 per share and to the trader's directional view on AKBA stock.
AKBA covered call setup
The AKBA covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AKBA at $0.88 on that close, the first option leg uses a $0.92 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AKBA chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AKBA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $0.88 | long |
| Sell 1 | Call | $0.92 | N/A |
AKBA covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
AKBA covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on AKBA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on AKBA
Covered calls on AKBA are an income strategy run on existing AKBA stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
AKBA thesis for this covered call
The market-implied 1-standard-deviation range for AKBA extends from approximately $0.80 on the downside to $0.96 on the upside. A AKBA covered call collects premium on an existing long AKBA position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether AKBA will breach that level within the expiration window. Current AKBA IV rank near 2.70% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AKBA at 31.30%. As a Healthcare name, AKBA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AKBA-specific events.
AKBA covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AKBA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AKBA alongside the broader basket even when AKBA-specific fundamentals are unchanged. Short-premium structures like a covered call on AKBA carry tail risk when realized volatility exceeds the implied move; review historical AKBA earnings reactions and macro stress periods before sizing. Always rebuild the position from current AKBA chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on AKBA?
- A covered call on AKBA is the covered call strategy applied to AKBA (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With AKBA stock at $0.88 on the most recent close, the strikes shown on this page are snapped to the nearest listed AKBA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are AKBA covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the AKBA covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 31.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AKBA covered call?
- The breakeven for the AKBA covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The AKBA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 8.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on AKBA?
- Covered calls on AKBA are an income strategy run on existing AKBA stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current AKBA implied volatility affect this covered call?
- AKBA ATM IV is at 31.30% with IV rank near 2.70%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.